These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 360760)

  • 1. Dopaminergic agonist Ro 8-4650 in Parkinson's disease. II. Patients not treated with dopa.
    Presthus J; Ankerhus J; Burén A; Bøttcher J; Holmsen R; Mikkelsen B; Mikkelsen BO; Nyberg-Hansen R; Riman E; Severin B; Aarli JA
    Acta Neurol Scand; 1978 Jul; 58(1):77-9. PubMed ID: 360760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic agonist Ro 8-4650 in Parkinson's disease. I. Patients treated with dopa.
    Birket-Smith E; Bøttcher J; Dupont E; Holm P; Jensen JP; Kristensen O; Køhler O; Mikkelsen B
    Acta Neurol Scand; 1978 Jul; 58(1):74-6. PubMed ID: 360759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomifensine in parkinsonism.
    Park DM; Findley LJ; Teychenne PF
    Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):185S-186S. PubMed ID: 334222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.
    Agid Y; Pollak P; Bonnet AM; Signoret JL; Lhermitte F
    Lancet; 1979 Mar; 1(8116):570-2. PubMed ID: 85162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomifensine in Parkinson's disease.
    Bedard P; Parkes JD; Marsden CD
    Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):187S-190S. PubMed ID: 334223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.
    Corsini GU; Del Zompo M; Gessa GL; Mangoni A
    Lancet; 1979 May; 1(8123):954-6. PubMed ID: 87620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
    Couto B; Oliveira C; Mattos JP; Freitas MR
    Neurol Neurocir Psiquiatr; 1976; 17(4):285-92. PubMed ID: 798128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocryptine in levodopa response-losing parkinsonism. A double blind study.
    Jansen EN
    Eur Neurol; 1978; 17(2):92-9. PubMed ID: 344042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonist monotherapy in Parkinson's disease.
    Clarke CE; Guttman M
    Lancet; 2002 Nov; 360(9347):1767-9. PubMed ID: 12480442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group.
    Arch Neurol; 1994 Apr; 51(4):342-7. PubMed ID: 8155011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromocriptine in the treatment of advanced Parkinsonism.
    Kristensen O; Hansen E
    Acta Neurol Scand; 1977 Sep; 56(3):274-6. PubMed ID: 333856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA.
    Andersen J; Aabro E; Gulmann N; Hjelmsted A; Pedersen HE
    Acta Neurol Scand; 1980 Oct; 62(4):210-9. PubMed ID: 7010875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.